Abstract
Insulin-like growth factor-1 (IGF-I) is a growth and survival factor in human multiple myeloma (MM) cells. Here we examine the effect of IGF-I on MM cell adhesion and migration, and define the role of β1 integrin in these processes. IGF-I increases adhesion of MM.1S and OPM6 MM cells to fibronectin (FN) in a time- and dose-dependent manner, as a consequence of IGF-IR activation. Conversely, blocking anti-β1 integrin monoclonal antibody, RGD peptide, and cytochalasin D inhibit IGF-I-induced cell adhesion to FN. IGF-I rapidly and transiently induces association of IGF-IR and β1 integrin, with phosphorylation of IGF-IR, IRS-1, and p85 PI3-K. IGF-I also triggers phosphorylation of AKT and ERK significantly. Both IGF-IR and β1 integrin colocalize to lipid rafts on the plasma membrane after IGF-I stimulation. In addition, IGF-I triggers polymerization of F-actin, induces phosphorylation of p125 FAK and paxillin, and enhances β1 integrin interaction with these focal adhesion proteins. Importantly, using pharmacological inhibitors of phosphatidylinositol 3′-kinase (PI3-K) (LY294002 and wortmannin) and extracellular signal-regulated kinase (PD98059), we demonstrate that IGF-I-induced MM cell adhesion to FN is achieved only when PI3-K/AKT is activated. IGF-I induces a 1.7-2.2 (MM.1S) and 2-2.5-fold (OPM6) increase in migration, whereas blocking anti-IGF-I and anti-β1 integrin monoclonal antibodies, PI3-K inhibitors, as well as cytochalasin D abrogate IGF-I-induced MM cell transmigration. Finally, IGF-I induces adhesion of CD138+ patient MM cells. Therefore, these studies suggest a role for IGF-I in trafficking and localization of MM cells in the bone marrow microenvironment. Moreover, they define the functional association of IGF-IR and β1 integrin in mediating MM cell homing, providing the preclinical rationale for novel treatment strategies targeting IGF-I/IGF-IR in MM.
Original language | English |
---|---|
Pages (from-to) | 5850-5858 |
Number of pages | 9 |
Journal | Cancer Research |
Volume | 63 |
Issue number | 18 |
Publication status | Published - 15 Sept 2003 |
Externally published | Yes |
Keywords
- Antibodies, Monoclonal/pharmacology
- Cell Adhesion/drug effects
- Cell Line, Tumor
- Cell Movement/drug effects
- Enzyme Activation
- Fibronectins/metabolism
- Humans
- Insulin-Like Growth Factor I/antagonists & inhibitors
- Integrin beta1/metabolism
- Membrane Glycoproteins/metabolism
- Membrane Microdomains/metabolism
- Mitogen-Activated Protein Kinase 1/antagonists & inhibitors
- Mitogen-Activated Protein Kinase 3
- Mitogen-Activated Protein Kinases/antagonists & inhibitors
- Multiple Myeloma/enzymology
- Oligopeptides/pharmacology
- Phosphatidylinositol 3-Kinases/metabolism
- Phosphoinositide-3 Kinase Inhibitors
- Protein Serine-Threonine Kinases
- Proteoglycans/metabolism
- Proto-Oncogene Proteins/metabolism
- Proto-Oncogene Proteins c-akt
- Receptor Cross-Talk/physiology
- Receptor, IGF Type 1/metabolism
- Signal Transduction/physiology
- Syndecan-1
- Syndecans
ASJC Scopus subject areas
- Oncology
- Cancer Research